Drug Profile
Research programme: cancer therapeutics - Aurigene Oncology/Debiopharm
Alternative Names: Debio 0617B; Debio 1142; Debio-0616; Debio-0617Latest Information Update: 15 Jan 2024
Price :
$50
*
At a glance
- Originator Aurigene Discovery Technologies; Debiopharm
- Developer Aurigene Oncology; Debiopharm
- Class Small molecules
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in India
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Switzerland
- 20 Jun 2013 Preclinical development is ongoing in Switzerland & India